HIGHLIGHTS
- who: Maryam Oskoui from the (UNIVERSITY) have published the research work: Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA), in the Journal: (JOURNAL) of 30/09/2020
- what: The authors report 24-month efficacy and safety results in this population. The authors investigate the efficacy and safety of 1 year of risdiplam treatment in patients who previously received placebo up to month 12. This trial was approved by an ethics committee at each study site and was conducted in accordance with Good . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.